Programs targeting muscle and metabolic disease through GRK2-biased β₂-adrenergic modulation.
Insulin-independent glucose uptake via GRK2→mTORC2→GLUT4. Exercise-mimetic effects on muscle preservation and metabolic function. Next: ATTRACTIVE 3 proof-of-concept.
Muscle-sparing complement to GLP-1 receptor agonists. Preclinical combo data shows prevention of liraglutide-induced muscle loss. Next: ATTRACTIVE 4.
Advanced muscle-sparing GLP-1 complement. Preclinical combo data shows accelerated healthy weight loss and prevention of liraglutide-induced muscle degradation. Next: Toxicology studies.
Extended compound library targeting sarcopenia, cachexia, and FSHD. 1,000+ rationally designed compounds. Lead selection underway.